Dihydroartemisinin/Piperaquine

DRUG4 trials

Sponsors

Oxford University Clinical Research Unit, Vietnam, London School of Hygiene and Tropical Medicine

Conditions

Malaria PaediatricsMalaria, FalciparumMalaria,FalciparumPlasmodium Vivax Malaria

Phase 2

Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission

CompletedNCT04049916

London School of Hygiene and Tropical MedicineMalaria,Falciparum

Start: 2019-09-12End: 2020-01-07Updated: 2020-01-30

Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

CompletedNCT04609098

London School of Hygiene and Tropical MedicineMalaria, Falciparum

Start: 2020-10-29End: 2020-12-23Updated: 2022-06-09

Phase 4

Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam

CompletedNCT01887821

Oxford University Clinical Research Unit, VietnamPlasmodium Vivax Malaria

Start: 2013-02-28End: 2015-06-30Updated: 2016-09-30

Unknown Phase

ACT SENSITIVITY SURVEILLANCE IN KENYA [retrospectively registered]

RecruitingPACTR201111000316370

Malaria Paediatrics

Start: 2010-03-01Target: 466Updated: 2026-01-27

Related Papers

Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.

2022-03-2318 citations

Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent <i>Plasmodium falciparum</i> malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial.

2022-01-0130 citations

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study.

2014-01-2842 citations